State Street Corp Buys 948,638 Shares of Edwards Lifesciences Co. (NYSE:EW)

State Street Corp lifted its stake in Edwards Lifesciences Co. (NYSE:EWGet Rating) by 3.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,920,713 shares of the medical research company’s stock after buying an additional 948,638 shares during the quarter. State Street Corp owned about 4.31% of Edwards Lifesciences worth $3,487,578,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of the company. Brown Advisory Inc. lifted its holdings in Edwards Lifesciences by 18.0% during the fourth quarter. Brown Advisory Inc. now owns 16,722,298 shares of the medical research company’s stock valued at $2,166,375,000 after purchasing an additional 2,548,909 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Edwards Lifesciences by 4.9% during the 4th quarter. Geode Capital Management LLC now owns 11,099,842 shares of the medical research company’s stock valued at $1,434,219,000 after buying an additional 517,261 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in Edwards Lifesciences by 5.6% in the 4th quarter. Fisher Asset Management LLC now owns 6,782,302 shares of the medical research company’s stock worth $878,647,000 after buying an additional 357,605 shares during the period. Capital Research Global Investors increased its stake in Edwards Lifesciences by 7.9% in the 3rd quarter. Capital Research Global Investors now owns 6,398,861 shares of the medical research company’s stock worth $724,418,000 after buying an additional 465,759 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in Edwards Lifesciences by 0.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,564,901 shares of the medical research company’s stock valued at $591,382,000 after acquiring an additional 32,891 shares during the period. 82.54% of the stock is currently owned by hedge funds and other institutional investors.

EW stock opened at $101.12 on Friday. Edwards Lifesciences Co. has a 52-week low of $91.52 and a 52-week high of $131.73. The firm has a market cap of $62.87 billion, a P/E ratio of 41.44, a PEG ratio of 2.85 and a beta of 1.16. The company’s 50-day simple moving average is $109.85 and its 200-day simple moving average is $113.06. The company has a quick ratio of 2.64, a current ratio of 3.41 and a debt-to-equity ratio of 0.10.

Edwards Lifesciences (NYSE:EWGet Rating) last announced its earnings results on Tuesday, April 26th. The medical research company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.02. The business had revenue of $1.34 billion during the quarter, compared to the consensus estimate of $1.31 billion. Edwards Lifesciences had a return on equity of 25.80% and a net margin of 28.72%. The business’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.54 EPS. On average, analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Several analysts recently issued reports on EW shares. Zacks Investment Research raised Edwards Lifesciences from a “sell” rating to a “hold” rating and set a $115.00 target price on the stock in a research note on Friday, April 29th. Citigroup lowered their target price on shares of Edwards Lifesciences from $134.00 to $115.00 and set a “buy” rating on the stock in a report on Tuesday, May 17th. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, May 5th. Canaccord Genuity Group reduced their price target on shares of Edwards Lifesciences from $152.00 to $137.00 in a report on Wednesday, April 27th. Finally, Sanford C. Bernstein raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $132.00 to $135.00 in a report on Wednesday, March 16th. Five investment analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $128.26.

In related news, VP Donald E. Bobo, Jr. sold 11,050 shares of the stock in a transaction dated Friday, March 11th. The stock was sold at an average price of $106.00, for a total transaction of $1,171,300.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Michael A. Mussallem sold 32,550 shares of the stock in a transaction dated Tuesday, May 10th. The shares were sold at an average price of $94.82, for a total value of $3,086,391.00. Following the completion of the sale, the chief executive officer now directly owns 157,353 shares in the company, valued at approximately $14,920,211.46. The disclosure for this sale can be found here. Over the last three months, insiders sold 235,840 shares of company stock valued at $25,404,659. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile (Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Featured Stories

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.